RECOMBINANT-HUMAN-ERYTHROPOIETIN FOR LATE-ONSET ANEMIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION

Recombinant human erythropoietin (rHu EPO) has been reported to accele rate early erythroid reconstitution after bone marrow transplantation (BMT). We conducted a pilot study on rHu EPO for late-onset anemia in 9 patients after allogeneic BMT. The patients achieved initial erythro poietic recovery (hemoglobin (Hb) range 9.1-13.4, mean 10.8 g/dl), but then developed transplant-related anemia (Hb range 6.3-9.7, mean 8.2 g/dl) more than 50 days after BMT. This type of anemia was related to graft-versus-host disease (GVHD), cytomegalovirus infection, and/or im paired EPO secretion. The patients received 3000 or 12000 U of rHu EPO subcutaneously three or seven times weekly. Hb levels increased by mo re than 2 g/dl in 6 of the 9 patients, but were unchanged in the 3 pat ients with severe GVHD. These findings suggest that in some cases rHu EPO is effective for the treatment of late-onset anemia after BMT. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.